Treatment Patterns and Outcomes of Multiple Myeloma Patients Undergoing Second-Line Therapy: A Canadian Myeloma Research Group (CMRG) Analysis
Clinical Lymphoma Myeloma and Leukemia · 2025
DOI: 10.1016/j.clml.2025.02.011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Arleigh McCurdy und 18 weiteren Autor:innen. Beteiligte Einrichtung: The Ottawa Hospital, Ottawa, Ontario, Canada. Electronic address: amccurdy@toh.ca. Hauptthemen laut MEDLINE: Multiple Myeloma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Janssen Canada, Johnson & Johnson Services Inc.
Abstract (Originalsprache)
INTRODUCTION: First-line treatment in Canadian transplant-eligible MM patients is CyBorD/RVD followed by ASCT and maintenance lenalidomide. In transplant ineligible patients, bortezomib- or lenalidomide-based treatment is used. Relapse options include salvage ASCT or diverse doublet/triplets. Limited data support any one approach. The aim of this study was to assess treatment patterns/outcomes of real-world patients at first relapse. METHODS: All patients initiating second-line therapy from January 1/10 to June 30/22 were included. We evaluated ORR, PFS and OS, calculated from the start of second-line. RESULTS: A total of 3569 patients were included, 1638 (45.9%) with prior ASCT and 1931 (54.1%) without. The most used regimens were Rd, DRd, CyBorD, ASCT, RVd and DVd. The highest ORRs were seen with DRd (90%), ASCT (89%), Kd/KCd (79%), RVd (78.1%) and KRd (74%). For drug regimens, median PFS (27.6 months) and OS (75.5 months) were longest for DRd. CONCLUSIONS: We evaluated impact of second-line treatment in MM patients. Triplets with an IMiD backbone and carfilzomib combinations had high ORR and durable PFS, with select patients undergoing second ASCT achieving durable responses. Given the expanding use of IMiD, PI and CD38 mAbs frontline, our results highlight the need for modern modalities at first relapse and provide a benchmark for implementation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Ottawa Hospital, Ottawa, Ontario, Canada. Electronic address: amccurdy@toh.ca.
- Canadian Myeloma Research Group, Vaughan, Ontario, Canada.
- Canadian Myeloma Research Group, Vaughan, Ontario, Canada; Princess Margaret Cancer Centre, Toronto, Canada.
- Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada.
- Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada.
- London Regional Cancer Center, London, Ontario, Canada.
Förderung
- Janssen Canada
- Johnson & Johnson Services Inc
Zitieren
APA
McCurdy, A., Gul, E., Reece, D., Chu, M. P., Jimenez-Zepeda, V. H., Louzada, M., Song, K., Mian, H., Sebag, M., White, D., Stakiw, J., Reiman, A., Bergstrom, D., Kotb, R., Aslam, M., Kaedbey, R., Venner, C. P., Su, J., & LeBlanc, R. (2025). Treatment Patterns and Outcomes of Multiple Myeloma Patients Undergoing Second-Line Therapy: A Canadian Myeloma Research Group (CMRG) Analysis. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.02.011
Vancouver
McCurdy A, Gul E, Reece D, Chu MP, Jimenez-Zepeda VH, Louzada M, et al. Treatment Patterns and Outcomes of Multiple Myeloma Patients Undergoing Second-Line Therapy: A Canadian Myeloma Research Group (CMRG) Analysis. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.02.011
BibTeX
@article{McCurdy2025,
author = {McCurdy, Arleigh and Gul, Engin and Reece, Donna and Chu, Michael P and Jimenez-Zepeda, Victor H and Louzada, Martha and Song, Kevin and Mian, Hira and Sebag, Michael and White, Darrell and Stakiw, Julie and Reiman, Anthony and Bergstrom, Debra and Kotb, Rami and Aslam, Muhammad and Kaedbey, Rayan and Venner, Christopher P and Su, Jiandong and LeBlanc, Richard},
title = {Treatment Patterns and Outcomes of Multiple Myeloma Patients Undergoing Second-Line Therapy: A Canadian Myeloma Research Group (CMRG) Analysis},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2025},
doi = {10.1016/j.clml.2025.02.011}
}
EUVIMED